TABLE 1.
Basic characteristics and outcomes of patients included in genome‐wide association analysis
| Variables | Results |
|---|---|
| Baseline characteristics | |
| Total patients | 170 |
| Regimen of dabigatran | 110 mg (n = 170), twice daily |
| Female, n (%) | 67 (39.4) |
| Age (years) | 72.0 (65.8, 79.0) |
| Bodyweight (kg) a | 70.7 ± 12.51 |
| BMI (kg/m2) a | 25.4 ± 3.69 |
| CREA (μmol/L) a | 83.8 ± 19.51 |
| eGFR (ml/min/1.73 m2) a | 73.6 (58.6, 88.6) |
| ALT (IU/L) a | 19.0 (14.0, 27.4) |
| AST (IU/L) a | 20.0 (16.0, 25.0) |
| HGB (g/L) a | 136.0 (121.5, 147.0) |
| PLT (109/L) a | 195.0 (162.0, 239.0) |
| MPV (fl) a | 9.4 (8.4, 10.9) |
| EF (%) a | 63.9 (58.8, 70.6) |
| CHA2DS2‐VASc score | 2.0 (1.75, 3.0) |
| HAS‐BLED score | 4.0 (3.0, 5.0) |
| Comorbidities, n (%) | |
|---|---|
| Hypertension | 121 (71.2) |
| Diabetes mellitus | 58 (34.1) |
| Stroke or TIA | 56 (32.9) |
| Coronary heart disease | 76 (44.7) |
| Myocardial infarction | 7 (4.1) |
| Heart failure | 27 (15.9) |
| PCI | 14 (8.2) |
| Catheter ablation a | 39 (34.8) |
| Co‐medications, n (%) | |
|---|---|
| ACEIs or ARBs a | 73 (43.5) |
| Beta‐blockers a | 95 (56.9) |
| Calcium channel blockers a | 64 (38.3) |
| Statins a | 103 (61.7) |
| Antiplatelet drugs a | 19 (11.3) |
| Nitrate esters a | 14 (12.1) |
| Proton‐pump inhibitors a | 33 (19.8) |
| Pharmacodynamic parameters | ||
|---|---|---|
| Trough levels | Peak levels | |
| Patients with tests, n (%) | 151 | 155 |
| Anti‐IIa activity (ng/ml) | 68.16 ± 60.34 | 150.62 ± 128.00 b |
| APTT (s) | 39.55 ± 9.90 | 48.29 ± 13.73 |
| PT (s) | 13.72 ± 6.11 | 14.09 ± 3.62 |
| Events, n (%) | |||
|---|---|---|---|
| Bleeding | TE | MACE | |
| 0–1 month (n = 169) | 7 (4.1) | 2 (1.2) | 0 (0.0) |
| 2–6 months (n = 149) | 11 (7.4) | 2 (1.3) | 2 (1.3) |
| 7–12 months (n = 122) | 12 (9.8) | 3 (2.5) | 4 (3.3) |
| 13–24 months (n = 51) | 3 (5.9) | 2 (3.9) | 2 (3.9) |
Note: For the continuous variables in baseline characteristics, data in normal distribution are shown as ‘mean ± SD’, and in skewed distribution are shown as ‘median (25, 75 percentiles)’.
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; ARB, angiotensin receptor blockers; AST, aspartate aminotransferase; BMI, body mass index; CREA, creatinine; EF, ejection fraction; eGFR, estimate glomerular filtrate rate; HGB, haemoglobin; MACE, major adverse cardiac event; MPV, mean platelet volume; PCI, percutaneous coronary intervention; PLT, platelet; PT, prothrombin time; TE, thromboembolic event; TIA, transient ischaemic attack.
The number of the variable was the number of observed values, excluding missing values.
The number of peak anti‐IIa activity tests was 156.